These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 33247328)
21. Characteristics and outcomes of patients with lymphoma who developed therapy-related acute myeloid leukemia or myelodysplastic syndrome - a retrospective analysis of the Polish Adult Leukemia Group. Gołos A; Mikulski D; Grobelska-Kowalik M; Mądry K; Lis K; Sobas M; Ożańska A; Czemerska M; Hawrylecka D; Stelmach-Gołdyś A; Chromik K; Puła B; Sobczyk-Kruszelnicka M; Góra-Tybor J Contemp Oncol (Pozn); 2024; 28(2):149-157. PubMed ID: 39421707 [TBL] [Abstract][Full Text] [Related]
22. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166 [TBL] [Abstract][Full Text] [Related]
23. Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study. Kusne Y; Lasho T; Finke C; Elsabbagh Z; McCue S; Hobday T; Starr J; Bekaii-Saab T; Halfdanarson TR; Patnaik MM; Ou FS; Sonbol MB JCO Precis Oncol; 2024 Jun; 8():e2400143. PubMed ID: 38976813 [TBL] [Abstract][Full Text] [Related]
24. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432 [TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830 [TBL] [Abstract][Full Text] [Related]
26. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. Ornstein MC; Mukherjee S; Mohan S; Elson P; Tiu RV; Saunthararajah Y; Kendeigh C; Advani A; Kalaycio M; Maciejewski JP; Sekeres MA Am J Hematol; 2014 Feb; 89(2):168-73. PubMed ID: 24123154 [TBL] [Abstract][Full Text] [Related]
27. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798 [TBL] [Abstract][Full Text] [Related]
28. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective. Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203 [TBL] [Abstract][Full Text] [Related]
29. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy. Yordanova A; Wicharz MM; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Fimmers R; Essler M; Ahmadzadehfar H Clin Cancer Res; 2018 Oct; 24(19):4672-4679. PubMed ID: 29950352 [No Abstract] [Full Text] [Related]
30. The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors. Yalchin M; Oliveira A; Theocharidou E; Pencharz D; Navalkissoor S; Quigley AM; Walker M; Caplin M; Toumpanakis C Clin Nucl Med; 2017 Mar; 42(3):e135-e141. PubMed ID: 27922860 [TBL] [Abstract][Full Text] [Related]
31. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296 [TBL] [Abstract][Full Text] [Related]
32. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039 [TBL] [Abstract][Full Text] [Related]
33. Predictive Value of Asphericity in Pretherapeutic [ Wetz C; Apostolova I; Steffen IG; Hofheinz F; Furth C; Kupitz D; Ruf J; Venerito M; Klose S; Amthauer H Mol Imaging Biol; 2017 Jun; 19(3):437-445. PubMed ID: 27743210 [TBL] [Abstract][Full Text] [Related]
34. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial. Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434 [TBL] [Abstract][Full Text] [Related]
35. Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. Heckert JM; Kipnis ST; Kumar S; Botterbusch S; Alderson A; Bennett B; Creamer C; Eads JR; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Katona BW Oncologist; 2020 Jul; 25(7):572-578. PubMed ID: 32141667 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis. Katona BW; Roccaro GA; Soulen MC; Yang YX; Bennett BJ; Riff BP; Glynn RA; Wild D; Nicolas GP; Pryma DA; Teitelbaum UR; Metz DC Pancreas; 2017 Oct; 46(9):1121-1126. PubMed ID: 28902781 [TBL] [Abstract][Full Text] [Related]
37. The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis. Yang Y; Tang Z; An T; Zhao L Medicine (Baltimore); 2019 Oct; 98(40):e17406. PubMed ID: 31577751 [TBL] [Abstract][Full Text] [Related]
38. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553 [TBL] [Abstract][Full Text] [Related]
39. Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors. Adnan A; Kudachi S; Ramesh S; Prabhash K; Basu S Nucl Med Commun; 2019 Sep; 40(9):947-957. PubMed ID: 31343606 [TBL] [Abstract][Full Text] [Related]
40. Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia. Wu Z; Chen R; Wu L; Zou L; Ding F; Wang M; Liu X Clin Transl Oncol; 2017 Dec; 19(12):1462-1468. PubMed ID: 28589431 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]